Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zepatier

EU flag

EU approval for J&J’s hepatitis C drug

Olysio can be used in combination with Gilead’s Sovaldi

- PMLiVE

Merck’s first-in-class Zontivity cleared in US

FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk

EU flag

AbbVie’s hep C combo gets priority review in Europe

EMA to fast track drug for use in hard-to-treat genotype 1 strain of HCV

- PMLiVE

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

WHO raises red flag on hepatitis C drug pricing

Warns about cost of Gilead’s Sovaldi and J&J’s Olysio

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

Bristol-Myers Squibb (BMS) building

BMS’ oral hepatitis C regimen gets breakthrough status

Combines daclatasvir and asunepravir

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

Merck turns to gamification in diabetes

Working with Ayogo on mobile app to improve adherence

- PMLiVE

FDA backs a brace of allergy immunotherapies

Merck & Co and Stallergenes win drug approvals in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links